fenofibrate has been researched along with 2019 Novel Coronavirus Disease in 10 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| " According to literature study reports several analytical techniques have been used for determination of FEN alone or in the combined dosage forms." | 3.01 | An Investigative Review for Pharmaceutical Analysis of Fenofibrate. ( Asati, V; Dhiman, S; Gupta, GD; Saha, M, 2023) |
| "Aging is associated with functional deficits in the naive T cell compartment, which compromise the generation of de novo immune responses against previously unencountered Ags." | 1.72 | Altered Basal Lipid Metabolism Underlies the Functional Impairment of Naive CD8 ( Appay, V; Boddaert, J; Cabral-Piccin, MP; Caputo, A; Clave, E; Dubois, M; Dupré, L; Folcher, V; Frere, JJ; Fusaro, M; Gallerani, E; Gavioli, R; Gostick, E; Llewellyn-Lacey, S; Nicoli, F; Papagno, L; Price, DA; Toubert, A; Vallet, H, 2022) |
| "Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide." | 1.56 | Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. ( Buschard, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 10 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feher, M | 1 |
| Joy, M | 1 |
| Munro, N | 1 |
| Hinton, W | 1 |
| Williams, J | 1 |
| de Lusignan, S | 1 |
| Nicoli, F | 1 |
| Cabral-Piccin, MP | 1 |
| Papagno, L | 1 |
| Gallerani, E | 1 |
| Fusaro, M | 1 |
| Folcher, V | 1 |
| Dubois, M | 1 |
| Clave, E | 1 |
| Vallet, H | 1 |
| Frere, JJ | 1 |
| Gostick, E | 1 |
| Llewellyn-Lacey, S | 1 |
| Price, DA | 1 |
| Toubert, A | 1 |
| Dupré, L | 1 |
| Boddaert, J | 1 |
| Caputo, A | 1 |
| Gavioli, R | 1 |
| Appay, V | 1 |
| Saha, M | 1 |
| Dhiman, S | 1 |
| Gupta, GD | 1 |
| Asati, V | 1 |
| Chirinos, JA | 2 |
| Lopez-Jaramillo, P | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Dávila-Del-Carpio, GH | 1 |
| Bizri, AR | 1 |
| Andrade-Villanueva, JF | 1 |
| Salman, O | 1 |
| Cure-Cure, C | 1 |
| Rosado-Santander, NR | 1 |
| Cornejo Giraldo, MP | 1 |
| González-Hernández, LA | 1 |
| Moghnieh, R | 1 |
| Angeliki, R | 1 |
| Cruz Saldarriaga, ME | 1 |
| Pariona, M | 1 |
| Medina, C | 1 |
| Dimitroulis, I | 1 |
| Vlachopoulos, C | 1 |
| Gutierrez, C | 1 |
| Rodriguez-Mori, JE | 1 |
| Gomez-Laiton, E | 1 |
| Cotrina Pereyra, R | 1 |
| Ravelo Hernández, JL | 1 |
| Arbañil, H | 1 |
| Accini-Mendoza, J | 1 |
| Pérez-Mayorga, M | 1 |
| Milionis, C | 1 |
| Poulakou, G | 1 |
| Sánchez, G | 1 |
| Valdivia-Vega, R | 1 |
| Villavicencio-Carranza, M | 1 |
| Ayala-García, RJ | 1 |
| Castro-Callirgos, CA | 1 |
| Alfaro Carrasco, RM | 1 |
| Garrido Lecca Danos, W | 1 |
| Sharkoski, T | 1 |
| Greene, K | 1 |
| Pourmussa, B | 1 |
| Greczylo, C | 1 |
| Ortega-Legaspi, J | 1 |
| Jacoby, D | 1 |
| Chittams, J | 1 |
| Katsaounou, P | 1 |
| Alexiou, Z | 1 |
| Sympardi, S | 1 |
| Sweitzer, NK | 1 |
| Putt, M | 1 |
| Cohen, JB | 2 |
| Ehrlich, A | 1 |
| Ioannidis, K | 1 |
| Nasar, M | 1 |
| Abu Alkian, I | 1 |
| Daskal, Y | 1 |
| Atari, N | 1 |
| Kliker, L | 1 |
| Rainy, N | 1 |
| Hofree, M | 1 |
| Shafran Tikva, S | 1 |
| Houri, I | 1 |
| Cicero, A | 1 |
| Pavanello, C | 1 |
| Sirtori, CR | 1 |
| Deutsch, L | 1 |
| Cohen, M | 1 |
| Gottlieb, A | 1 |
| Bar-Chaim, A | 1 |
| Shibolet, O | 1 |
| Mandelboim, M | 1 |
| Maayan, SL | 1 |
| Nahmias, Y | 1 |
| Huang, J | 1 |
| Chan, KC | 1 |
| Zhou, R | 1 |
| Khalaji, A | 1 |
| Behnoush, AH | 1 |
| Alilou, S | 1 |
| Rezaee, M | 1 |
| Peiman, S | 1 |
| Sahebkar, A | 1 |
| Lee, HJ | 1 |
| Choi, H | 1 |
| Nowakowska, A | 1 |
| Kang, LW | 1 |
| Kim, M | 1 |
| Kim, YB | 1 |
| Buschard, K | 1 |
| Heffernan, KS | 1 |
| Ranadive, SM | 1 |
| Jae, SY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
2 reviews available for fenofibrate and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
An Investigative Review for Pharmaceutical Analysis of Fenofibrate.
Topics: Chromatography, High Pressure Liquid; COVID-19; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reduc | 2023 |
Adjunctive therapy with lipid-lowering agents in COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Topics: COVID-19; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2023 |
2 trials available for fenofibrate and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019.
Topics: Adult; Aged; COVID-19; Female; Fenofibrate; Humans; Lipid Metabolism; Male; Middle Aged; PPAR alpha; | 2022 |
Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study.
Topics: COVID-19; Fenofibrate; Humans; Lipids; PPAR alpha; Prospective Studies; SARS-CoV-2; Treatment Outcom | 2023 |
6 other studies available for fenofibrate and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality.
Topics: COVID-19; Fenofibrate; Humans; Hypolipidemic Agents; Laboratories; Pharmaceutical Preparations; SARS | 2021 |
Altered Basal Lipid Metabolism Underlies the Functional Impairment of Naive CD8
Topics: Adult; Aged; Aged, 80 and over; Aging; Apoptosis; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell | 2022 |
Novel Inhibitory Role of Fenofibric Acid by Targeting Cryptic Site on the RBD of SARS-CoV-2.
Topics: COVID-19; Fenofibrate; Humans; Molecular Dynamics Simulation; Protein Binding; SARS-CoV-2; Spike Gly | 2023 |
Antiviral Activity Against SARS-CoV-2 Variants Using in Silico and in Vitro Approaches.
Topics: Antiviral Agents; COVID-19; Fenofibrate; Humans; Molecular Docking Simulation; SARS-CoV-2 | 2023 |
Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.
Topics: Adult; Aging; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy.
Topics: Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytoplasm; | 2020 |